RedHill Biopharma Terminates License Agreement For Aemcolo, A Treatment For Traveler's Diarrhea, Will Be Officially Terminated On October 8, 2024
Author: Benzinga Newsdesk | July 09, 2024 08:12am
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision with Cosmo Technologies Ltd. ("Cosmo") to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea (the "License Agreement"). The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.
Posted In: RDHL